Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma.

Clinical lung cancer - 1 May 2017

Genestreti Giovenzio, de Biase Dario, Di Battista Monica, Cavallo Giovanna, Degli Esposti Roberta, Visani Michela, Acquaviva Giorgia, Brand Thomas, Pession Annalisa, Tallini Giovanni, Brandes Alba A

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Drug-Related Side Effects and Adverse Reactions
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dyspnea

Share to Gefitinib

Share to Pleural Effusion

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 28162944
DOI: 10.1016/j.cllc.2017.01.003

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma.PMID 28162944Read ↗

Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation.Semantic proximity Read ↗

Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.Semantic proximity Read ↗

Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.Semantic proximity Read ↗

The EGFR Exon 19 Mutant L747-A750&gt;P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung AdenocarcinomaSemantic proximity Read ↗

A rare EGFR mutation L747P conferred therapeutic efficacy to both geﬁtinib and osimertinib: A case report.Semantic proximity Read ↗

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.Semantic proximity Read ↗

EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.Semantic proximity Read ↗

A rare EGFR exon 19 insertion mutation in metastatic lung adenocarcinoma: a favorable response to afatinib.Semantic proximity Read ↗

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.Semantic proximity Read ↗

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.Semantic proximity Read ↗

A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.Semantic proximity Read ↗

EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.